Literature DB >> 22575687

Infective and inactivated filamentous phage as carriers for immunogenic peptides.

Tatiana I Samoylova1, Mandy D Norris, Alexandre M Samoylov, Anna M Cochran, Karen G Wolfe, Valery A Petrenko, Nancy R Cox.   

Abstract

The focus of this study is on development of vaccines using filamentous phage as a delivery vector for immunogenic peptides. The use of phage as a carrier for immunogenic peptides provides significant benefits such as high immunogenicity, low production costs, and high stability of phage preparations. However, introduction of live recombinant phage into the environment might represent a potential ecological problem. This, for example, may occur when vaccines are used in oral or nasal formulations in field conditions for wild and feral animals. To address this issue, comparative studies of antigenic properties of live and inactivated (non-viable) phage were accomplished. Inactivated phage, if released, will not propagate and will degrade as any other protein. In these experiments, a model phage clone that was previously selected from a phage display library and shown to stimulate production of anti-sperm antibodies with contraceptive properties was used. Multiple methods of phage inactivation were tested, including drying, freezing, autoclaving, heating, and UV irradiation. Under studied conditions, heating at 76°C for 3h, UV irradiation, and autoclaving resulted in complete phage inactivation. Phage samples treated by heat and UV were characterized by spectrophotometry and electron microscopy. To test antigenicity, live and inactivated phage preparations were injected into mice and antibody responses assayed by ELISA. It was found that phage killed by heat causes little to no immune responses, probably due to destruction of phage particles. In contrast, UV-inactivated phage stimulated production of IgG serum antibodies at the levels comparable to live phage. Thus, vaccines formulated to include UV-inactivated filamentous phage might represent environmentally safe alternatives to live phage vaccines.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22575687     DOI: 10.1016/j.jviromet.2012.03.032

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  10 in total

1.  Identification and characterization of a peptide affinity reagent for detection of noroviruses in clinical samples.

Authors:  Jennifer D Rogers; Nadim J Ajami; Bartlomiej G Fryszczyn; Mary K Estes; Robert L Atmar; Timothy Palzkill
Journal:  J Clin Microbiol       Date:  2013-04-03       Impact factor: 5.948

2.  Real-Time qPCR as a Method for Detection of Antibody-Neutralized Phage Particles.

Authors:  Anna Kłopot; Adriana Zakrzewska; Dorota Lecion; Joanna M Majewska; Marek A Harhala; Karolina Lahutta; Zuzanna Kaźmierczak; Łukasz Łaczmański; Marlena Kłak; Krystyna Dąbrowska
Journal:  Front Microbiol       Date:  2017-11-06       Impact factor: 5.640

3.  Phage proteins are expressed on the surface of Neisseria gonorrhoeae and are potential vaccine candidates.

Authors:  Aneta Kłyż; Andrzej Piekarowicz
Journal:  PLoS One       Date:  2018-08-23       Impact factor: 3.240

Review 4.  Arming Filamentous Bacteriophage, a Nature-Made Nanoparticle, for New Vaccine and Immunotherapeutic Strategies.

Authors:  Rossella Sartorius; Luciana D'Apice; Antonella Prisco; Piergiuseppe De Berardinis
Journal:  Pharmaceutics       Date:  2019-09-01       Impact factor: 6.321

Review 5.  A combination therapy of Phages and Antibiotics: Two is better than one.

Authors:  Xianghui Li; Yuhua He; Zhili Wang; Jiacun Wei; Tongxin Hu; Jiangzhe Si; Guangzhao Tao; Lei Zhang; Longxiang Xie; Abualgasim Elgaili Abdalla; Guoying Wang; Yanzhang Li; Tieshan Teng
Journal:  Int J Biol Sci       Date:  2021-08-18       Impact factor: 6.580

Review 6.  Beyond phage display: non-traditional applications of the filamentous bacteriophage as a vaccine carrier, therapeutic biologic, and bioconjugation scaffold.

Authors:  Kevin A Henry; Mehdi Arbabi-Ghahroudi; Jamie K Scott
Journal:  Front Microbiol       Date:  2015-08-04       Impact factor: 5.640

7.  Phage Peptide Libraries As a Source of Targeted Ligands.

Authors:  A A Nemudraya; V A Richter; E V Kuligina
Journal:  Acta Naturae       Date:  2016 Jan-Mar       Impact factor: 1.845

8.  Oral Immunization of Rabbits with S. enterica Typhimurium Expressing Neisseria gonorrhoeae Filamentous Phage Φ6 Induces Bactericidal Antibodies Against N. gonorrhoeae.

Authors:  Andrzej Piekarowicz; Aneta Kłyż; Michał Majchrzak; Daniel C Stein
Journal:  Sci Rep       Date:  2016-03-04       Impact factor: 4.379

Review 9.  Immunocontraception: Filamentous Bacteriophage as a Platform for Vaccine Development.

Authors:  Tatiana I Samoylova; Timothy D Braden; Jennifer A Spencer; Frank F Bartol
Journal:  Curr Med Chem       Date:  2017-11-20       Impact factor: 4.530

10.  Vectorized Delivery of Alpha-GalactosylCeramide and Tumor Antigen on Filamentous Bacteriophage fd Induces Protective Immunity by Enhancing Tumor-Specific T Cell Response.

Authors:  Rossella Sartorius; Luciana D'Apice; Pasquale Barba; Deborah Cipria; Laura Grauso; Adele Cutignano; Piergiuseppe De Berardinis
Journal:  Front Immunol       Date:  2018-06-28       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.